Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)
D1.441 - A Bispecific Antibody Targeting IL13 and IL31 for the Treatment of Inflammatory Skin Diseases
D1.444 - Dual Blockade of IL22 and IL23 with a bispecific antibody: A Promising Strategy for the Treatment of Psoriasis and Other Autoimmune Skin Disorders
D3.17 - Outcomes of Anti-Tuberculosis Drug Reintroduction Following Adverse Drug Reactions among Adult Patients at a Tertiary Hospital in the Philippines (2022-2024)
D3.27 - Nivolumab-Induced Psoriasiform Eruption: Diagnostic Challenge Between Immune-Related Toxicity and Drug Allergy
D3.30 - Automated generation of structured clinical databases in drug hypersensitivity: real-world validation in patients with proton pump inhibitor reactions
D3.16 - Increase of Post–SARS-CoV-2 Rashes Mimicking Penicillin Allergy in Children with Group A beta-hemolytic Streptococcus Infection: an emerging and challenging issue
D3.18 - Role of an Allergological Work-up in Antibiotic Allergy Delabeling in Mexican Pediatric Patients
D3.20 - Study of “in vitro” cross reactivity between nsLTP’s comparing “in silico” results with a new specific IgE test based on immunoblot methodology
D3.21 - When the Patient Diagnoses Herself: Amoxicillin-Induced Acute Pancreatitis as a Rare Manifestation of Drug Hypersensitivity
D3.25 - Machine learning models to differentiate cross-reactive and selective-hypersensitive patients to nonsteroidal anti-inflammatory drugs hypersensitivity
D3.31 - Real-world Practices in the Diagnosis and Evaluation of Allergic Rhinitis among Korean Specialists
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download